ABUS vs OGN · P/E 5.4, rev $6.2M vs P/E 3.4, rev $6.40B
Arbutus Biopharma Corp (ABUS) versus Organon & Co (OGN) — a side-by-side from cached financials, not a winner call.
Arbutus Biopharma Corp (ABUS) is a biotechnology company listed on NASDAQ.
Organon & Co (OGN) is a drug manufacturers - general company listed on US.
Latest reported ABUS revenue for 2024-12-31 was $6.2M. Net income was -$69.9M. Revenue was down 66.0% from 2023-12-31 to 2024-12-31. ABUS currently screens at market cap $883.0M and trailing P/E 5.4.
Latest reported OGN revenue for 2024-12-31 was $6.40B. Net income was $864.0M. Revenue was up 2.2% from 2023-12-31 to 2024-12-31. OGN currently screens at market cap $2.52B and trailing P/E 3.4.
ABUS currently screens at market cap $883.0M and trailing P/E 5.4. OGN currently screens at market cap $2.52B and trailing P/E 3.4.
Not investment advice. Open the ABUS and OGN stock pages for the full models.
Not investment advice.